These examples clearly demonstrate the importance of natural product chemistry in identifying the structures of bioactive molecules and developing therapeutic agents. Despite their high pharmacological potential, medicinal plants possess complex chemical compositions, which adds complexity to the drug discovery process [2]. A single plant species may contain hundreds of primary and secondary metabolites, with concentrations influenced by factors such as genetic traits, geographical distribution, climatic conditions, soil composition, developmental stage, time of harvest, and post-harvest processing. Consequently, the pharmacological properties of plant extracts can vary significantly from one sample to another, even when derived from the same botanical species [3]. This chemical variability presents challenges in identifying the specific compounds responsible for observed biological effects and in developing reproducible therapeutic preparations. Typically, the traditional approach to medicinal plant research involves the collection of plant material, extraction, preliminary phytochemical screening, chromatographic separation, compound isolation, and biological evaluation. While these methods can identify many bioactive molecules, the process can be time-consuming and may fail to detect compounds present in low concentrations, chemically unstable substances, or compounds that exert their biological effects through synergistic interactions [4]. And the attributing pharmacological activity to specific phytochemical constituents—based solely on the assessment of crude extracts that lack comprehensive chemical characterization—can lead to inaccurate conclusions.

Recent advancements in analytical and computational sciences have opened new avenues for addressing these challenges. Sophisticated chromatographic techniques, high-resolution mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, and metabolomics now enable a more detailed chemical analysis of plants. Concurrently, molecular docking, molecular dynamics simulations, pharmacological modeling, network pharmacology, and artificial intelligence (AI)-based screening facilitate the analysis of potential molecular targets and the biological processes involved [6]. By integrating these approaches, chemical composition can be linked to pharmacological activity and interactions at the molecular level. It must be emphasized that computational predictions alone cannot confirm therapeutic effects; predicted interactions require experimental validation through biochemical and cellular assays, as well as appropriate in vivo studies. The use of traditional medicine should be viewed as a starting point for formulating research hypotheses, rather than as sufficient evidence of clinical efficacy. Therefore, a multidisciplinary approach—combining phytochemistry, pharmacology, molecular biology, computational chemistry, and toxicology—is essential to transform resources derived from medicinal plants into scientifically validated drug candidates [7]. This review article discusses the fundamental steps in drug discovery from medicinal plants, focusing on the integration of phytochemical research, pharmacological evaluation, molecular characterization, and computational methods. The current limitations and highlight emerging approaches that can improve the reproducibility of results, deepen the understanding of mechanisms of action, and enhance the translational potential of plant-derived medicines.

2. Ethnopharmacological Approaches in Medicinal Plant-Based Drug Discovery

Ethnopharmacology serves as a fundamental basis for the discovery of plant-derived medicines by investigating the links between traditional therapeutic practices and the pharmacological properties of natural substances. Ethnobotanical documentation enables the identification of plant species used by local communities, encompassing their therapeutic applications, preparation methods, the specific plant parts utilized, routes of administration, and traditional dosages. This information acts as a guide for selecting plant species for subsequent phytochemical and pharmacological studies. Integrating ethnobotanical knowledge with contemporary experimental research allows for the establishment of a rational priority for the study of medicinal plants. Species with a documented history of traditional use for specific medical conditions can be selected for targeted pharmacological investigations. For example, plants traditionally employed to treat inflammatory conditions can be evaluated using biomarkers relevant to inflammation—such as cyclooxygenase enzymes, lipoxygenase pathways, the NF-κB transcription factor signaling pathway, or pro-inflammatory cytokine mediators [8]. Similarly, plants traditionally used for metabolic diseases can be studied by analyzing glucose metabolism pathways, insulin signaling, the inhibition of the enzyme α-glucosidase, and other related molecular targets. Selection based on ethnopharmacology must be supported by precise botanical identification and rigorous documentation. Confirming a plant’s identity through a qualified taxonomist, utilizing herbarium samples (known as “voucher specimens”), and consulting accredited botanical databases are essential steps to ensure the correct identification of the species under study [9]. Errors in identification, the substitution of raw materials, or their adulteration can compromise the reproducibility of experiments and lead to incorrect pharmacological interpretations [9]. Basic health research must be conducted in accordance with ethical research principles, including obtaining prior informed consent, serving the public interest, managing intellectual property, and promoting the equitable distribution of benefits. These aspects are particularly important when research involves indigenous peoples or biological resources from regions characterized by high biodiversity. The integration of advanced metabolomics and computational biology is increasingly recognized as an effective strategy for identifying natural products derived from plants. Recent “multi-omics” studies have demonstrated how ethnobotanical information can be combined with metabolite profiling, genomic data, and computational analysis to identify and characterize biologically active compounds.

3. Phytochemical Diversity and Its Importance in Drug Discovery

Plant secondary metabolites are a group of natural compounds characterized by immense chemical diversity; they play vital roles in plant defense mechanisms, ecological interactions, stress responses, pigmentation processes, and cell signaling [10]. Many of these metabolites exhibit pharmacological activity through interactions with enzymes, receptors, transport proteins, transcription factors, and cell signaling pathways. Their diverse chemical structures offer opportunities to identify new chemical entities and develop compounds with therapeutic potential.

3.1 Alkaloids

Alkaloids are nitrogen-containing secondary metabolites characterized by diverse molecular structures and pharmacological properties. These compounds frequently interact with neurotransmitter receptors, ion channels, enzymes, and nucleic acids. Many alkaloids are used for therapeutic purposes, underscoring their importance in drug research. Morphine, derived from the plant Papaver somniferum, exerts its effects primarily through opioid receptors and is widely used to alleviate severe pain. Quinine, obtained from species of the genus Cinchona, exhibits antimalarial activity by disrupting the detoxification process of the heme group within the parasite [11]. Berberine—found, for example, in plants of the genus Berberis—is currently being investigated for its antimicrobial, metabolic, and anti-inflammatory properties. Vincristine and vinblastine, isolated from the plant Catharanthus roseus, affect microtubule dynamics and are considered significant antitumor agents. The molecular complexity of alkaloids often enables them to participate in selective biological interactions. Nevertheless, the pharmacological evaluation of alkaloids must also account for dose-dependent toxicity, metabolic transformation, and potential interactions with other therapeutic agents.

3.2 Flavonoids

Flavonoids are polyphenolic compounds commonly found in medicinal plants, fruits, vegetables, and other plant-derived products. Their major subclasses include flavones, flavonols, flavanones, flavan-3-ols, isoflavones, and anthocyanins. Well-known examples within this group include quercetin, kaempferol, catechin, epigallocatechin gallate, luteolin, and apigenin. Flavonoids are the subject of extensive research due to the mechanisms by which they provide protection against oxidative damage, inflammation, pathogenic microorganisms, cardiovascular disorders, neurodegeneration, and cancer [12]. These effects are mediated through various biological processes, such as the regulation of oxidative stress, the modulation of inflammatory mediators, the inhibition of specific enzymes, and interaction with intracellular signaling pathways. For instance, quercetin has been studied for its ability to modulate signaling pathways such as PI3K/Akt, MAPK, and NF-κB. Epigallocatechin gallate has been extensively analyzed regarding its effects on oxidative stress, inflammatory responses, and molecular pathways associated with cancer; however, when interpreting these findings, careful consideration must be given to the concentrations achievable within the body, the extent to which the compound is metabolized, and the body’s capacity to utilize it.

3.3 Terpenoids and Terpenes

Terpenoids constitute the largest group of plant metabolites, derived from isoprene units. This group encompasses monoterpenes, sesquiterpenes, diterpenes, triterpenes, and tetraterpenes. Their structural characteristics enable these compounds to interact with a wide range of biological targets. Artemisinin, obtained from Artemisia annua, is a well-known example of a plant-based antimalarial drug. Paclitaxel, derived from the genus Taxus, is an established anticancer agent; it functions by stabilizing microtubules and inhibiting normal cell division. Other terpenoids—such as ursolic acid, oleanolic acid, and limonene—have been studied for their anti-inflammatory, antibacterial, metabolic-regulating, and anticancer properties [13]. The development of terpenoid-based therapeutic agents requires careful consideration of their chemical stability, solubility, metabolic profile, and structural characteristics.

3.4 Phenolic Acids and Tannins

Phenolic acids and tannins are plant-derived polyphenolic compounds that exhibit various biological effects. Phenolic acids—including, for example, gallic, caffeic, ferulic, and chlorogenic acids—are studied for their antioxidant, anti-inflammatory, and metabolic properties. Tannins are generally classified into hydrolyzable and condensed types. Their biological functions may include protein binding, enzyme inhibition, the regulation of oxidative stress, and interaction with the cellular structures of microorganisms [14]. At the same time, due to their strong binding capacity, they can also influence the absorption of nutrients and the bioavailability of other compounds.

3.5 Glycosides and Other Specialized Metabolites

Glycosides consist of a carbohydrate component linked to a non-carbohydrate moiety, often referred to as an aglycone. Their pharmacological properties can depend on the chemical structure of the aglycone, the glycosylation pattern, and metabolic transformations by gut microorganisms or host enzymes. Saponins, cardiac glycosides, anthraquinone glycosides, and cyanogenic glycosides represent important categories of plant-derived glycosides [15]. Some of these compounds have therapeutic applications, while others 4. Extraction, Isolation and Purification of Bioactive Phytochemicals

The extraction and isolation of bioactive compounds constitute essential stages in medicinal plant-based drug discovery. The efficiency of phytochemical recovery depends on several factors, including plant species, selected plant organs, particle size, solvent polarity, temperature, extraction duration, and solvent-to-material ratio [16]. Appropriate extraction procedures are necessary to obtain representative chemical fractions while minimizing the degradation of thermolabile and oxidation-sensitive compounds.

4.1 Conventional Extraction Techniques

Maceration, infusion, decoction, percolation, and Soxhlet extraction are commonly used methods for obtaining phytochemical extracts. Maceration involves soaking powdered plant material in a suitable solvent under controlled conditions. It is relatively simple and suitable for temperature-sensitive constituents, although prolonged extraction may be required. Soxhlet extraction provides continuous solvent circulation through the plant material and is useful for recovering compounds with suitable thermal stability [17]. Infusion and decoction are particularly relevant when investigating traditional aqueous preparations because they approximate commonly used herbal preparation methods.

4.2 Advanced Extraction Techniques

Recent advances in extraction technology have improved the recovery, selectivity, and efficiency of plant-derived compounds. Ultrasound-assisted extraction facilitates solvent penetration and mass transfer through cavitation effects. Microwave-assisted extraction enhances extraction efficiency through rapid heating of suitable solvent–plant systems. Supercritical fluid extraction, particularly using carbon dioxide, offers opportunities for extracting relatively non-polar compounds while reducing organic solvent consumption [18]. Pressurized liquid extraction and enzyme-assisted extraction have also gained importance because they can improve the recovery of selected phytochemical groups under optimized conditions.

4.3 Bioactivity-Guided Fractionation

Bioactivity-guided fractionation connects chemical separation with biological screening. Initially, crude plant extracts are evaluated using selected pharmacological assays. Active extracts are subsequently separated into fractions using chromatographic techniques, and each fraction is tested independently. Further purification of active fractions may lead to the identification of individual compounds responsible for the observed activity. However, this approach requires careful interpretation because the activity of a crude extract may depend on interactions among several constituents [19]. The isolation of individual compounds can sometimes result in reduced activity if synergistic or additive effects are lost. Therefore, both isolated compounds and reconstructed combinations should be evaluated where scientifically justified.

4.4 Chromatographic Separation and Compound Purification

Thin-layer chromatography (TLC), high-performance thin-layer chromatography (HPTLC), high-performance liquid chromatography (HPLC), gas chromatography (GC), and preparative chromatography are widely used for phytochemical separation and purification. HPLC provides effective separation of compounds with different physicochemical characteristics, whereas GC–MS is particularly useful for volatile and thermally stable constituents. LC–MS/MS facilitates the characterization of complex mixtures containing compounds with different molecular masses and fragmentation patterns [20]. The selection of chromatographic techniques should be based on the chemical characteristics of the target compounds. Furthermore, the purity of isolated compounds should be evaluated using appropriate analytical methods rather than inferred solely from the presence of a chromatographic spot or a matching retention time.

5. Advanced Analytical Approaches for Phytochemical Characterization

Accurate identification and structural characterization are essential for establishing the chemical identity of candidate phytochemicals. Modern analytical platforms provide complementary information regarding molecular mass, functional groups, chemical connectivity, and stereochemical properties.

5.1 High-Performance Liquid Chromatography

HPLC is commonly employed for the separation, quantification, and quality assessment of plant-derived compounds. Reversed-phase HPLC using C18 stationary phases is frequently used for analysing phenolic compounds, flavonoids, and other moderately polar metabolites [21]. Quantification using authentic reference standards enables the determination of individual compound concentrations and supports the development of standardized chemical fingerprints. HPLC coupled with diode-array detection provides additional information through UV–Visible absorption profiles.

5.2 Gas Chromatography–Mass Spectrometry

GC–MS is particularly valuable for identifying volatile constituents, essential oils, fatty acid derivatives, and suitable low-molecular-weight compounds. The mass spectra obtained from chromatographically separated components can be compared with established spectral libraries to facilitate tentative compound identification. However, library matching alone should not be considered definitive structural confirmation. Authentic standards, retention indices, and complementary analytical evidence improve identification confidence.

5.3 Liquid Chromatography–Tandem Mass Spectrometry

LC–MS/MS enables sensitive analysis of complex phytochemical mixtures and is especially useful for detecting compounds present at relatively low concentrations. High-resolution mass spectrometry provides accurate mass measurements and facilitates molecular formula prediction. Tandem mass spectrometry provides fragmentation information that can support the annotation of chemical structures. Untargeted metabolomics uses these techniques to compare the chemical profiles of different plant samples, extraction conditions, developmental stages, and treatment groups. Targeted metabolomics, in contrast, focuses on the detection and quantification of predefined metabolites.

5.4 Nuclear Magnetic Resonance Spectroscopy

NMR spectroscopy provides important structural information through the chemical environments and connectivity of atoms within a molecule. One-dimensional techniques, including ¹H-NMR and ¹³C-NMR, are routinely employed in structural elucidation. Two-dimensional methods, such as COSY, HSQC, and HMBC, provide additional information regarding proton–proton and proton–carbon correlations. NMR is particularly important when identifying novel natural products or distinguishing between structurally related phytochemicals. Combining NMR with accurate mass spectrometry can substantially strengthen structural assignments.

5.5 Fourier Transform Infrared Spectroscopy

FTIR spectroscopy identifies characteristic functional groups through molecular vibrational absorption. It can provide information about hydroxyl, carbonyl, aromatic, ether, and other functional groups in plant extracts and isolated compounds. However, FTIR spectra alone generally cannot establish complete molecular structures or confirm the identity of individual compounds in complex mixtures. The combination of chromatographic separation, mass spectrometry, NMR, and spectroscopic characterization provides a stronger basis for identifying and validating candidate phytochemicals.

6. Pharmacological Screening and Biological Validation

Pharmacological evaluation determines whether identified phytochemicals demonstrate biological activities relevant to specific disease conditions. An integrated screening strategy should progress from preliminary biochemical assays to cellular studies, mechanistic investigations, and appropriate animal models when justified.

6.1 Antioxidant Activity

Oxidative stress results from an imbalance between reactive oxygen species generation and antioxidant defence mechanisms. It contributes to several pathological processes, including inflammation, metabolic disorders, cardiovascular abnormalities, and neurodegenerative conditions. Medicinal plant extracts and isolated phytochemicals are frequently evaluated using DPPH, ABTS, FRAP, and related antioxidant assays. These methods provide preliminary information about radical-scavenging and reducing properties. However, chemical antioxidant activity in cell-free systems does not necessarily translate into biological antioxidant efficacy. Therefore, cellular assays examining intracellular ROS, glutathione status, lipid peroxidation, and antioxidant enzyme activities are important for further validation.

6.2 Anti-inflammatory Activity

Inflammation is regulated by interconnected molecular pathways involving cytokines, enzymes, transcription factors, and immune-cell signalling. Important molecular mediators include TNF-α, IL-1β, IL-6, COX-2, iNOS, and NF-κB. Plant-derived flavonoids, terpenoids, and phenolic compounds have been investigated for their potential to modulate inflammatory pathways. Experimental validation may involve measurement of inflammatory cytokines, nitric oxide production, prostaglandin synthesis, and pathway-associated protein expression.

6.3 Antimicrobial and Antiviral Activity

Medicinal plants provide numerous compounds with potential antimicrobial activity. Their effects may involve disruption of microbial membranes, inhibition of essential enzymes, interference with nucleic acid synthesis, and modulation of microbial virulence factors.

Antimicrobial investigations generally involve broth microdilution, agar diffusion, minimum inhibitory concentration, and minimum bactericidal concentration assays. Further studies should evaluate activity against relevant microbial strains and determine whether the observed effects are reproducible. For antiviral screening, suitable cell-based assays may be used to investigate viral replication, viral entry, and virus-associated cytopathic effects. Cytotoxicity controls are essential because apparent antiviral activity may result from nonspecific damage to host cells.

6.4 Anticancer Activity

Plant-derived compounds have made a substantial contribution to the development of anticancer drugs. Vincristine, vinblastine, and paclitaxel are examples of well-established plant-based anticancer therapies. Current research focuses on the regulation of cell proliferation, apoptosis, cell cycle progression, angiogenesis, and metastasis, as well as tumor-related signaling pathways. Common molecular targets include PI3K/Akt, MAPK, p53, the Bcl-2 protein family, caspases, and signaling pathways associated with VEGF. Initial screening typically employs cell viability assays, such as the MTT assay, the resazurin assay, or similar methods. However, a reduction in metabolic activity alone is insufficient to confirm the occurrence of apoptosis or a specific anticancer mechanism [22]. To elucidate the underlying biological mechanisms, additional experiments are required, including flow cytometry, measurement of caspase activity, gene expression analysis, and validation at the protein level.

6.5 Antidiabetic and Metabolic Activities

The possible effects of medicinal plant-derived compounds on carbohydrate metabolism, insulin sensitivity, glucose uptake, and regulation of lipid metabolism are under investigation. Studies measuring the inhibition of α-amylase and α-glucosidase activities provided preliminary insights into possible effects on carbohydrate digestion processes. Further research could explore areas such as the regulation of glucose transport, insulin signaling, AMPK activation, and analysis of metabolic biomarkers. The practical application of these findings requires consideration of bioavailability, achievable systemic concentrations, and potential side effects.

7. Molecular Approaches in Medicinal Plant-Based Drug Discovery

Molecular approaches provide a mechanistic framework for investigating how plant-derived compounds interact with biological targets. These techniques help bridge the gap between preliminary pharmacological observations and molecular-level explanations of therapeutic activity.

7.1 Molecular Docking

Molecular docking is a mathematical method used to predict the orientation of a small molecule as it interacts with a biological macromolecule. In research involving medicinal plants, toxicity is often considered when investigating possible interactions between plant components and molecular targets associated with various diseases. A typical workflow includes selection of a biologically relevant protein, extraction or production of its three-dimensional structure, identification of the binding site, preparation of structures of plant components, and estimation of relevant parameters [23]. The results are evaluated by labeling and the analysis of molecular interactions. Significant interactions include hydrogen bonds, hydrophobic interactions, electrostatic forces, π-π stacking, and van der Waals interactions. While the results may be useful in comparing and evaluating candidate compounds, they should not be interpreted as direct measurements of binding affinity or as definitive indicators of biological activity. Selection of appropriate reference ligands, validation of docking protocols, and ensuring the use of the correct protein structure are essential steps to improve the reliability of computational results.

7.2 Molecular Dynamics Simulations

Molecular dynamics (MD) simulations investigate the time-dependent behavior of molecular systems. Unlike traditional molecular docking, which typically evaluates a static or limited structural state, MD simulations provide insight into the dynamic stability of protein-ligand complexes under specific simulation conditions. Key analytical parameters include the root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration (Rg), hydrogen bonds, solvent-accessible surface area, and estimated binding free energy [24]. MD simulations can help identify structural changes, ligand stability, and interactions occurring within the environment of the bound protein. However, their interpretation depends on the duration of the simulation, the choice of force field, system preparation, the representation of the solvent, and sampling requirements.

7.3 Pharmacophore Modelling

Pharmacophore modelling identifies the essential molecular features associated with biological activity. These features may include hydrogen-bond donors, hydrogen-bond acceptors, aromatic centres, hydrophobic regions, and charged functional groups. Pharmacophore models can be generated using known active compounds or structural information from protein–ligand complexes. They can subsequently be used to screen phytochemical databases for compounds possessing similar molecular features.

7.4 Quantitative Structure–Activity Relationship Analysis

Quantitative structure–activity relationship (QSAR) modelling establishes mathematical relationships between molecular descriptors and experimentally measured biological activities. Descriptors may include molecular weight, lipophilicity, hydrogen-bonding capacity, topological properties, molecular fingerprints, and electronic characteristics. QSAR models can support the prioritization of phytochemicals and the identification of structural features associated with biological activity. Their reliability depends on dataset quality, chemical diversity, appropriate model validation, and applicability-domain assessment.

7.5 Network Pharmacology

Network pharmacology examines the relationships between various compounds, biological targets, signaling pathways, and disease-related processes. This approach is particularly useful in research on medicinal plants, as crude extracts and traditional formulations may contain numerous interacting components. A typical workflow involves identifying plant metabolites, searching for or predicting potential protein targets, gathering disease-associated genes, and constructing a compound-target-pathway network. Network analysis can help identify highly interconnected targets and pathways, which then warrant experimental investigation [25]. Predicted compound-target associations must be distinguished from interactions that have been experimentally verified. Centrality within a network does not, by itself, determine therapeutic significance, and associations derived from databases may also contain errors.

8. Integration of Phytochemistry, Pharmacology and Molecular Approaches

Integrating plant chemistry, general chemistry, and molecular biology is an effective strategy for developing plant-based medicines. Rather than treating chemical profiling, biological assays, and computational modeling as separate activities, an integrated approach connects these components through empirical validation. In the initial phase, phylogenetic data can be used to prioritize medicinal plant species. Following biological validation, plant extracts are prepared under controlled conditions. Analytical technologies—such as HPLC, LC-MS/MS, and NMR—are employed to identify and quantify chemical constituents. Subsequently, phytochemical data and the results of biological assays are synthesized to identify active compounds and synergistic components [26]. Molecular docking and pharmacokinetic analysis can then be utilized to prioritize molecular targets and mechanisms of action. Selected candidate compounds can be evaluated through molecular dynamics simulations and the analysis of ADMET properties prior to further experimental investigation. Importantly, candidates prioritized via computational methods require subsequent experimental testing for validation. In vivo studies can reveal drug-induced effects, cellular assays can assess biological responses, and appropriate animal studies can provide deeper insights into efficacy, toxicity, and pharmacokinetics.

9. Pharmacokinetics, Bioavailability and Toxicological Evaluation

The identification of phytochemicals that exhibit promising in vitro biological activity does not automatically guarantee their suitability as drug candidates. Many natural compounds are characterized by poor aqueous solubility, limited gastrointestinal absorption, rapid metabolism, high protein-binding affinity, or inadequate distribution to target tissues. Pharmacokinetic evaluation encompasses the processes of absorption, distribution, metabolism, and excretion. ADMET profiling can provide preliminary insights into these properties and assist in prioritizing compounds for further experimental investigation. Factors such as lipophilicity, molecular weight, hydrogen-bonding capacity, polar surface area, and chemical stability all influence the pharmacokinetic profile of phytochemicals. Compounds with low aqueous solubility may require specialized formulation strategies to enhance their dissolution and absorption. Other compounds may undergo extensive first-pass metabolism, which reduces their systemic bioavailability [27]. Toxicological evaluation is equally critical; plant-derived compounds are not inherently safe, as their biological effects can vary based on dosage, duration of exposure, metabolic transformation, and interactions with other substances. Certain medicinal plants contain components that may be hepatotoxic, nephrotoxic, cardiotoxic, or genotoxic. Initial safety assessments may include cytotoxicity assays, hemolysis tests, genotoxicity monitoring, and the analysis of biomarkers for liver and kidney function. Further research must employ appropriate, validated models and adhere to established ethical and regulatory standards. The potential interactions between medicinal plants and conventional treatments must be considered, as plant-derived compounds can influence enzymes and transporters involved in drug metabolism, including cytochrome P450 enzymes and P-glycoprotein. Interactions of this kind can alter the level of exposure to conventional drugs and affect their therapeutic effects.

10. Standardization, Quality Control and Reproducibility

Standardization is a fundamental requirement for transforming drug research into a manufacturable drug development process. Variations in plant genetics, geographical origin, environmental conditions, cultivation methods, harvesting time, and processing techniques can influence the chemical composition of plant material. Authentication of plant material should be supported by appropriate taxonomic documentation and reference specimens (vouchers). Chemical standardization should be based on validated analytical methods, selected marker compounds, and a reproducible chromatographic profile. Quality assessment should also take into account microbial contamination, pesticide residues, heavy metals, mycotoxins, and any other external contaminants. Adoption of Good Agricultural and Collection Practices (GACP), combined with appropriate oversight in the production process, can enhance the consistency and safety of substances derived from medicinal plants. For purified substances originating from plants, it is necessary to verify the identity, purity, structural confirmation, stability, and consistency between batches within the batch using appropriate analytical methods. In the case of standardized extracts, the chemical profiles and concentrations of the selected marker compounds should be monitored throughout the production process [28]. Therefore, the development of validated analytical methods is essential to ensure that pharmacological results can be replicated in different laboratories and translated into reliable therapeutic products.

11. Challenges and Limitations in Medicinal Plant-Based Drug Discovery

Despite significant technological progress, several challenges continue to restrict the translation of medicinal plant research into clinically useful drugs.

Complexity of plant extracts: The presence of numerous chemically related metabolites makes it difficult to identify individual active constituents and distinguish their biological contributions.

Chemical variability: Environmental conditions, seasonal changes, geographical distribution, and post-harvest processing can alter the phytochemical composition of medicinal plants.

Limitations of preliminary pharmacological screening: Many studies rely primarily on antioxidant or enzyme-inhibition assays without establishing whether the observed activities are biologically relevant at achievable concentrations.

Computational prediction limitations: Molecular docking, network pharmacology, and machine learning can generate hypotheses, but predicted interactions require experimental validation.

Poor pharmacokinetic properties: Limited solubility, low oral bioavailability, rapid metabolism, and inadequate tissue distribution may prevent promising phytochemicals from reaching effective concentrations.

Toxicological uncertainty: Insufficient investigation of chronic exposure, reproductive toxicity, genotoxicity, and herb–drug interactions may compromise the safety of plant-derived candidates.

Insufficient clinical evidence: Many medicinal plants have been evaluated only through in vitro experiments or preliminary animal studies. Well-designed clinical trials remain necessary to establish therapeutic effectiveness and safety in humans.

Intellectual property and biodiversity concerns: The use of traditional knowledge and biological resources requires ethical documentation, legal compliance, and appropriate benefit-sharing mechanisms.

12. Future Perspectives and Emerging Research Directions

The future of drug discovery based on medicinal plants will increasingly depend on the integration of analytical, bioanalytical, and computational technologies, as well as chemical engineering. Advances in high-throughput metabolomics are expected to improve the identification of compounds present at low concentrations, enabling comparisons across different plant species, entire regions, and ecosystems. Integrating a “multi-omics” approach represents another significant research direction: combining metabolomics with other biochemical disciplines can help define the relationships between biological pathways, metabolic synthesis, and pharmacological activity. Such methods may lead to the identification of bioactive enzymes involved in the synthesis of valuable natural products. Artificial intelligence has the potential to enhance plant analysis by integrating large volumes of chemical data with biochemical data. Predictive models can help identify new molecular structures with pharmacological activity, optimize molecular design, and prioritize candidates for experimental research. However, the development of reliable, AI-supported methods requires up-to-date data and independent experimental validation.

Another promising approach involves investigating synergistic interactions among phytochemicals. Rather than focusing exclusively on isolated molecules, future studies could examine whether specific combinations exhibit additive, synergistic, or antagonistic effects. Such investigations should employ appropriate quantitative methods, including combination index analysis and dose-response modeling. Nanotechnology and advanced drug delivery systems can enhance the pharmacological properties of plant-derived compounds. Nanoformulations, liposomes, polymeric nanoparticles, and lipid-based delivery systems are being explored to improve solubility, stability, controlled release, and drug distribution. However, any formulation-related improvements must be supported by pharmacokinetic and toxicological testing. The sustainable production of metabolites from medicinal plants is equally important. Plant culture, the cultivation of modified plants (“weeds”), metabolic engineering, and synthetic biology offer alternative methods for producing valuable phytochemicals and reducing pressure on plant populations. Success in clinical drug discovery will require a shift from predominantly functional observation toward systematic, discovery-based, and mechanism-based investigations. This approach should link the identification of plant metabolites to their interaction with molecular targets, pharmacokinetic behavior, toxicological assessment, and clinical evaluation.

13. Conclusion

Medicinal plants remain valuable resources for discovering bioactive compounds with diverse structures and for developing new therapeutic approaches. Their role in modern pharmacology underscores the importance of natural products in determining the structures of biologically active drugs. However, translating traditional knowledge regarding medicinal plants requires thorough botanical verification, characterization, chemical analysis, and validation at the molecular level. The integration of advanced chromatographic and biochemical techniques provides a systematic approach for identifying and characterizing the active constituents of plants. Technologies such as molecular docking, molecular dynamics simulations, QSAR modeling, in silico pharmacokinetic analysis, and artificial intelligence serve as complementary tools for understanding potential molecular interactions and prioritizing prospective targets. Scientific hypotheses must be supported by robust experimental data, and pharmacological findings require validation through the use of biological, cellular, and in vivo models. Furthermore, factors such as variability in pharmacokinetics, bioavailability, toxicity, compatibility, and clinical reproducibility can influence the development of potential medicinal herbal products. Multidisciplinary approaches—combining botany, chemistry, biology, and mathematics—provide an effective framework for advancing the discovery of drugs derived from medicinal plants. Such an integrated approach would encourage scientific validation and lead to the development of safer, standardized, and clinically relevant herbal therapies.

References

1. Chihomvu, P., Ganesan, A., Gibbons, S., Woollard, K., & Hayes, M. A. (2024). Phytochemicals in drug discovery—A confluence of tradition and innovation. International journal of molecular sciences, 25(16), 8792.
2. Nasim, N., Sandeep, I. S., & Mohanty, S. (2022). Plant-derived natural products for drug discovery: current approaches and prospects. The Nucleus, 65(3), 399-411.
3. Babalola, Olorunfemi Oyewole, Kpomah Bridget, Godspower Oyubu, Sakariyau Adio Waheed, Samuel Ayomikun Ajiboye, Aderonke Elizabeth Fakayode, Adeleye Adegboyega Edema et al. “Integrating phytochemicals and in silico methods for modern drug discovery: a comprehensive review.” Discover Chemistry 2, no. 1 (2025): 297.
4. Chaachouay, N., & Zidane, L. (2024). Plant-derived natural products: a source for drug discovery and development. Drugs and Drug Candidates, 3(1).
5. Sinha, D., Odoh, U. E., Ganguly, S., Muhammad, M., Chatterjee, M., Chikeokwu, I., & Egbuna, C. (2023). Phytochemistry, history, and progress in drug discovery. In Phytochemistry, computational tools and databases in drug discovery (pp. 1-26). Elsevier.
6. Katiyar, Chandrakant, Arun Gupta, Satyajyoti Kanjilal, and Shefali Katiyar. “Drug discovery from plant sources: An integrated approach.” Ayu 33, no. 1 (2012): 10.
7. Shukla, A. K., Pradhan, J., Kumar, M., Panchawat, S., & Jain, C. P. (2025). Computational techniques for drug discovery from medicinal plants. In Plant biotechnology (pp. 223-244). CRC Press.
8. Das, A. P., & Agarwal, S. M. (2024). Recent advances in the area of plant-based anti-cancer drug discovery using computational approaches. Molecular Diversity, 28(2), 901-925.
9. Bhat, S. S., Sindhu, R., & Prasad, S. K. (2024). A bioinformatics approach towards plant-based anticancer drug discovery. In Computational approaches in biotechnology and bioinformatics (pp. 35-60). CRC Press.
10. Vig, H., Wal, A., Khanam, Z., Nigam, A., & Pandey, V. K. (2026). Artificial Intelligence-powered Advances in Phytomedicine: A Systematic Review on Plant-based Drug Discovery Software. Current Drug Discovery Technologies, 23(5), E15701638388155.
11. Süntar, I. (2020). Importance of ethnopharmacological studies in drug discovery: role of medicinal plants. Phytochemistry Reviews, 19(5), 1199-1209.
12. Jauhari, S., Jauhari, R., Rupanagunta, G. P., Nandave, M., Upadhyay, J., & Joshi, R. (2024). Insights on the integration of ethnopharmacology and omics in medicinal plant research. In Ethnopharmacology and OMICS Advances in Medicinal Plants Volume 2: Revealing the Secrets of Medicinal Plants (pp. 501-514). Singapore: Springer Nature Singapore.
13. Khan, S. R., Al Rijjal, D., Piro, A., & Wheeler, M. B. (2021). Integration of AI and traditional medicine in drug discovery. Drug discovery today, 26(4), 982-992.
14. Pirintsos, Stergios, Athanasios Panagiotopoulos, Michalis Bariotakis, Vangelis Daskalakis, Christos Lionis, George Sourvinos, Ioannis Karakasiliotis, Marilena Kampa, and Elias Castanas. “From traditional ethnopharmacology to modern natural drug discovery: A methodology discussion and specific examples.” Molecules 27, no. 13 (2022): 4060.
15. Nagarajan, Prithiviraj, Suganya Kannan, Anburaj Raj, Leena Rajathy Port Louis, Asbar Banu Bazeer, Ramachandran Kaliaperumal, Mariadoss Arokia Vijaya Anand, and Sharangouda J. Patil. “Future prospects in medicinal plant-derived drug development: unveiling opportunities and challenges.” Biotechnology and phytochemical prospects in drug discovery (2025): 241-266.
16. Singh, Kuldeep, Jeetendra Kumar Gupta, Dilip Kumar Chanchal, Manoj Gangadhar Shinde, Shivendra Kumar, Divya Jain, Zainab M. Almarhoon et al. “Natural products as drug leads: Exploring their potential in drug discovery and development.” Naunyn-Schmiedeberg’s Archives of Pharmacology 398, no. 5 (2025): 4673-4687.
17. AlSheikh, Hana Mohammed Al, Insha Sultan, Vijay Kumar, Irfan A. Rather, Hashem Al-Sheikh, Arif Tasleem Jan, and Qazi Mohd Rizwanul Haq. “Plant-based phytochemicals as possible alternative to antibiotics in combating bacterial drug resistance.” Antibiotics 9, no. 8 (2020): 480.
18. Pandey, S., & Yadav, P. (2025). Computational and AI Approach in Phytochemistry and Plant-Associated Drug-Designing. In Pharmacology of Plants and Plant Derived Biologically Active Molecules (pp. 289-320). CRC Press.
19. Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019). A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery. Metabolites, 9(11), 258.
20. Kalita, I., Bhattacharjee, S., & Saharia, M. (2025). Advancements in medicinal plant research: Harnessing artificial intelligence, machine learning, deep learning, and bioinformatics. In Biotechnology, Multiple Omics, and Precision Breeding in Medicinal Plants (pp. 135-145). CRC press.
21. Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018). Natural products for drug discovery in the 21st century: innovations for novel drug discovery. International journal of molecular sciences, 19(6), 1578.
22. Ghosh, D., Datta, N., Banerjee, D., Adhikary, S., Banerjee, S., & De, A. (2023). Current trends on phytochemicals toward herbal medicine development. In Herbal medicine phytochemistry: applications and trends (pp. 1-26). Cham: Springer International Publishing.
23. Manickavasagam, G., Mahendran, T. R., & Lim, V. (2024). Metabolomics and cancer: identification of biomarkers from plant-based pharmaceuticals using an integrated approach. In Cancers in Different Conditions, Cancer Research Methods and Diagnosis: An Interdisciplinary Approach (pp. 295-338). Cham: Springer Nature Switzerland.
24. Manickavasagam, G., Mahendran, T. R., & Lim, V. (2024). Metabolomics and cancer: identification of biomarkers from plant-based pharmaceuticals using an integrated approach. In Cancers in Different Conditions, Cancer Research Methods and Diagnosis: An Interdisciplinary Approach (pp. 295-338). Cham: Springer Nature Switzerland.
25. Krishnaswamy, S. (2024). Phytopharmaceutical biotechnology: Integration of botany, pharmacology and plant biotechnology to deliver the best therapeutic potential of herbs. In Concepts in pharmaceutical biotechnology and drug development (pp. 437-464). Singapore: Springer Nature Singapore.
26. Giri, K. R., Palandurkar, K., Trigunayat, A., & Giri, R. (2024). Reverse pharmacology: transdisciplinary approach of drug discovery from ethnomedicine. In Traditional Resources and Tools for Modern Drug Discovery: Ethnomedicine and Pharmacology (pp. 267-293). Singapore: Springer Nature Singapore.
27. Hao, D. C., He, C. N., Spjut, R. W., & Xiao, P. G. (2022). Plant-derived natural compounds in drug discovery: the prism perspective between plant phylogeny, chemical composition, and medicinal efficacy. Frontiers in Plant Science, 13, 1042695.
28. Saddiqa, A., Yaseen, R., Hassan, M., Aftab, K., & Iqbal, R. (2025). Bridging the Gap Between Herbs and Pharmaceutics: The Science Behind Herbs’ Medicinal Properties and Potential in Modern Drugs. Revista Brasileira de Farmacognosia, 35(5), 861-877.